Dexcom (DXCM) insider trade: 2,906 shares sold at $59.05

Rhea-AI Filing Summary

DexCom, Inc. director trade: A DexCom (DXCM) director reported selling 2,906 shares of common stock on 11/14/2025 at $59.05 per share. The transaction was executed by the Richard A. Collins Revocable Trust under a pre-arranged Rule 10b5-1 trading plan adopted on August 7, 2025, designed to allow orderly sales over time. Following this sale, the trust holds 35,088 DexCom shares indirectly for the reporting person, and the director also holds 5,074 unvested restricted stock units granted on May 8, 2025, which will vest on the earlier of one year from grant or DexCom’s 2026 annual meeting of stockholders.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Collins Richard Alexander

(Last) (First) (Middle)

6340 SEQUENCE DRIVE

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
DEXCOM INC [ DXCM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/14/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/14/2025		S		2,906(1)	D	$59.05	35,088	I	by Trust(2)
Common Stock								5,074(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On August 7, 2025, the Richard A. Collins Revocable Trust (the "Trust") adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by the Trust. The shares set forth above were sold pursuant to the 10b5-1 Plan.

2. Shares are held by the Richard A. Collins Revocable Trust, with respect to which the reporting person is a trustee.

3. Represents unvested restricted stock units which were granted on May 8, 2025 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2026 Annual Meeting of Stockholders.

Remarks:

	/s/ Jereme M. Sylvain, as Attorney-in-Fact for Richard Alexander Collins	11/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did DexCom (DXCM) disclose in this Form 4 filing?

The filing reports that a DexCom director, through the Richard A. Collins Revocable Trust, sold 2,906 shares of DexCom common stock on 11/14/2025 and updated the director’s remaining share and restricted stock unit holdings.

How many DexCom (DXCM) shares did the director sell and at what price?

The director, via the Revocable Trust, sold 2,906 shares of DexCom common stock at a price of $59.05 per share.

Was the DexCom (DXCM) share sale made under a Rule 10b5-1 plan?

Yes. The filing states that the Richard A. Collins Revocable Trust adopted a Rule 10b5-1 trading plan on August 7, 2025, and the reported shares were sold pursuant to that plan.

How many DexCom (DXCM) shares does the director still beneficially own after the sale?

After the reported transaction, the Revocable Trust holds 35,088 DexCom shares indirectly for the reporting person, according to the filing.

What unvested DexCom (DXCM) restricted stock units does the director hold?

The filing notes that the director holds 5,074 unvested restricted stock units, granted on May 8, 2025, which will vest on the earlier of the one-year anniversary of the grant date or DexCom’s 2026 annual meeting of stockholders.

What is the director’s relationship to the DexCom (DXCM) shareholding trust?

The shares are held by the Richard A. Collins Revocable Trust, and the reporting person serves as a trustee of that trust.